Antiphospholipid antibodies during 6-month treatment with infliximab: A preliminary report

BACKGROUND: The introduction of tumor necrosis factor (TNF) antagonists (adalimumab, infliximab, and etanercept) was a major advance and was highly important and beneficial in most rheumatoid arthritis (RA) patients. The adverse effects of this treatment are infrequent, but include opportunistic int...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolarz, Bogdan, Majdan, Maria, Darmochwał-Kolarz, Dorota A., Dryglewska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2014
Materias:
Preliminary Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109570/
https://www.ncbi.nlm.nih.gov/pubmed/25027437
http://dx.doi.org/10.12659/MSM.890270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109570/
https://www.ncbi.nlm.nih.gov/pubmed/25027437
http://dx.doi.org/10.12659/MSM.890270

Ejemplares similares